Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Half Year ended September 30, 2026 (Q2 FY26)

Nature of Filing / Announcement: Outcome of Board Meeting under Regulation 30 and 33 of SEBI LODR

Audit Opinion:

Unmodified opinion issued by statutory auditors MSKA & Associates LLP for both standalone and consolidated financial results.

Key Financial Highlights [Amount in lakhs of ₹]:

Consolidated Results:

Quarter Ended September 30, 2026:
  • Revenue from Operations: ₹44,965.69
  • Total Income: ₹45,715.22
  • Net Profit: ₹5,162.50
  • EPS: ₹40.24 (Basic and Diluted)
Half Year Ended September 30, 2026:
  • Revenue from Operations: ₹1,09,123.40
  • Total Income: ₹1,10,722.10
  • Net Profit: ₹19,929.81
  • EPS: ₹155.34 (Basic and Diluted)
Comparison with Previous Periods:
  • Q2 FY26 Net Profit decreased to ₹5,162.50 lakhs from ₹9,685.39 lakhs in Q2 FY25 (46.7% decline)
  • H1 FY26 Net Profit increased to ₹19,929.81 lakhs from ₹11,075.39 lakhs in H1 FY25 (79.9% increase)

Standalone Results:

Quarter Ended September 30, 2026:
  • Revenue from Operations: ₹44,965.69
  • Total Income: ₹45,715.03
  • Net Profit: ₹5,112.75
  • EPS: ₹39.85 (Basic and Diluted)
Half Year Ended September 30, 2026:
  • Revenue from Operations: ₹1,09,123.40
  • Total Income: ₹1,10,721.91
  • Net Profit: ₹19,848.94
  • EPS: ₹154.71 (Basic and Diluted)

Consolidated Statement of Assets and Liabilities as at September 30, 2026:

  • Total Assets: ₹3,02,955.83 lakhs
  • Total Equity: ₹2,02,970.96 lakhs
  • Cash and Cash Equivalents: ₹5,365.54 lakhs
  • Bank balances other than cash: ₹39,678.28 lakhs
  • Total Borrowings: ₹23,920.38 lakhs (Non-current: ₹20,072.16 lakhs, Current: ₹3,848.22 lakhs)
  • Other Equity: ₹2,01,680.91 lakhs

Segment-wise Performance:

The Group has only one reportable segment: "manufacture of active pharmaceutical ingredients and allied services"

Geography-wise Revenue for Q2 FY26:

  • India: ₹7,822.97 lakhs
  • Europe: ₹20,009.81 lakhs
  • USA and North America: ₹12,887.54 lakhs
  • Rest of the world: ₹4,245.37 lakhs

Non-current Assets by Geography:

  • India: ₹1,62,378.84 lakhs
  • Rest of the world: ₹3.46 lakhs

Corporate Actions:

Approved capital expenditure of ₹47.1 crores (including GST) for acquisition of a land parcel admeasuring Ac.6-00 Gts situated at Domadugu Village, Sangareddy District, Telangana, including other related expenditure.

Capital Expenditure Details:

  • Mode of Financing: Through internal accruals
  • Purpose: For future capacity expansion
  • Existing Capacity: Not applicable
  • Capacity Utilization: Not applicable
  • Proposed Capacity Addition: Not applicable
  • Period for capacity addition: Not applicable

Other Significant Information:

  • The consolidated financial results include two subsidiaries whose interim financial information was not reviewed by their auditors but were considered not material to the Group
  • Total comprehensive income for Q2 FY26: ₹5,127.38 lakhs (Consolidated), ₹5,092.12 lakhs (Standalone)
  • Equity share capital: ₹1,290.05 lakhs (129,005,000 equity shares of ₹10 each)